We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Graft Polymer (uk) Plc | GPL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.01 | -5.41% | 0.175 | 11:27:59 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.185 | 0.175 | 0.185 | 0.175 | 0.185 |
| Industry Sector |
|---|
| FOOD PRODUCERS |
| Top Posts |
|---|
Posted at 16/12/2024 11:40 by bri15 Tips for 2025, obviously GPL,plus FAB,ROCK,GSCU,GENF and possibly WCAT. |
Posted at 11/12/2024 07:44 by ssrover great result at #GPL The potential here is off the scale.Sub £5 mil Mcap for what we have here is, and let’s be honest here quite simply ridiculous. X that by 10 and I’d still feel super comfy given the global potential of these therapeutics, and the currently unmet need medical for these disorders. could be todays bagger or two |
Posted at 15/11/2024 15:07 by ssrover #GPL about to blast off.. full ask for small.. something defiantly brewing here.. literally no noise on twitter and bulletin boards |
Posted at 15/11/2024 13:02 by ssrover GPL near full ask now 21.98p.. reckon this goes again this afternoon awaiting news next week possibly even monday |
Posted at 14/11/2024 20:39 by ssrover #GPL in fact the more i think about it the more i feel #GPL is about to moon.. this deal in the same sector is incredible .. #GPL market cap £4m.. this deal is worth £2billion |
Posted at 14/11/2024 16:21 by ssrover #GPL days highs paid and 100m volume and zero interest on twitter and bulletin boards.. suggest someone is loading heavy prior to clinical trials due anytime.. last time it went from 0.1p to over 1p in two days |
Posted at 14/11/2024 09:11 by ssrover Myles McNulty@MylesMcNulty Graft Polymer #GPL has been climbing quietly under the radar the past three weeks, following the major pullback in the latter half of October. Now +50% since the lows. Definitely a buyer or two around. Do they know something? Probably. Eurofins study results due any day now, and I suspect new chairman Dennis Purcell has also been busy on new introductions and deals. As previously stated, I get the impression Dennis wants GPL as his preferred listed vehicle focusing on mental disorders. A mammoth new frontier in biotech. Graft Polymer’s existing technology is just the start for the Group. Quote |
Posted at 14/11/2024 09:08 by ssrover A very quick turnaround anticipated for this pre-clinical study being carried out by Eurofins on behalf of #GPL - possibly as fast as two weeks."The focus of this joint programme (with Awakn) is the development of next-generation medicines targeting trauma-related mental health conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a condition affecting approximately 13 million adults in the U.S. and 20 million individuals across the US, UK, and key European markets. The aminoindane series being developed shows great promise in modulating key neurotransmitter systems involved in mental health conditions like PTSD. By targeting serotonin, dopamine, and noradrenaline reuptake, this pharmacological testing could unlock new therapeutic pathways for addressing trauma-related disorders." True frontier stuff. Just a tad punchy, on the R/R scales...! In the meantime, expecting new chairman Dennis Purcell to swiftly open doors to further collaborations and investment. For me, a momentum play in its nascent stages. Tiny mkt cap (£4m at 0.18p), cashed up, and new mgmt and shareholders with big ideas to grow this vehicle. |
Posted at 13/11/2024 20:51 by ssrover 54m volume out of nowhere.. no twitter noise and no posts here… suggests a leak to me.. half decent clinical results and this bags many times over just like it did in junewhat’s more mind blowing is the appointment of the new CEO.. why is he here at a £4m cap company ? GPL “Dennis is Founder and Senior Advisor at Aisling Capital. During his tenure, Dennis has been directly involved with over two hundred completed transactions and supervised over $15 billion of financing and advisory assignments in the pharmaceutical” |
Posted at 27/9/2024 10:05 by smackeraim Watch the video below.. his previous deals are mind blowing. Came here excited about GPL patents and the research into new treatments for mental health issues. It's a huge market.. and affects many people. I've had some close friends to me that suffered over years so I'm obviously right behind things like this from a personal perspective.. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
